Mark Jacobson
Geschäftsführer bei AXSOME THERAPEUTICS, INC.
Vermögen: 424 646 $ am 31.05.2024
Profil
Mark L.
Jacobson is currently the Chief Operating Officer at Axsome Therapeutics, Inc. He previously worked as the Director of Corporate Development at Stemline Therapeutics, Inc. from 2009 to 2014.
Mr. Jacobson received his graduate degree from The Trustees of Columbia University in The City of New York in 2010 and his undergraduate degree from Iowa State University in 2006.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 29.05.2024 | 5 783 ( 0,01% ) | 424 646 $ | 31.05.2024 |
Aktive Positionen von Mark Jacobson
| Unternehmen | Position | Beginn |
|---|---|---|
| AXSOME THERAPEUTICS, INC. | Geschäftsführer | 01.04.2014 |
Ehemalige bekannte Positionen von Mark Jacobson
| Unternehmen | Position | Ende |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.03.2014 |
Ausbildung von Mark Jacobson
| Iowa State University | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AXSOME THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
